JP2023534009A5 - - Google Patents
Info
- Publication number
- JP2023534009A5 JP2023534009A5 JP2023501802A JP2023501802A JP2023534009A5 JP 2023534009 A5 JP2023534009 A5 JP 2023534009A5 JP 2023501802 A JP2023501802 A JP 2023501802A JP 2023501802 A JP2023501802 A JP 2023501802A JP 2023534009 A5 JP2023534009 A5 JP 2023534009A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- raf
- administered
- antibody
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051320P | 2020-07-13 | 2020-07-13 | |
| US63/051,320 | 2020-07-13 | ||
| PCT/US2021/041439 WO2022015736A1 (en) | 2020-07-13 | 2021-07-13 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534009A JP2023534009A (ja) | 2023-08-07 |
| JP2023534009A5 true JP2023534009A5 (enExample) | 2024-07-23 |
Family
ID=79554253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501802A Pending JP2023534009A (ja) | 2020-07-13 | 2021-07-13 | 異常な細胞成長を処置するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230330088A1 (enExample) |
| EP (1) | EP4178573A4 (enExample) |
| JP (1) | JP2023534009A (enExample) |
| KR (1) | KR20230039684A (enExample) |
| CN (1) | CN116056699A (enExample) |
| AU (1) | AU2021307410A1 (enExample) |
| BR (1) | BR112023000675A2 (enExample) |
| CA (1) | CA3189383A1 (enExample) |
| IL (1) | IL299789A (enExample) |
| MX (1) | MX2023000589A (enExample) |
| WO (1) | WO2022015736A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| WO2024178274A2 (en) * | 2023-02-24 | 2024-08-29 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods of degrading raf(raf) protein in cells using mitogen-activated protein kinase kinase 1/2 (mek1/2) protein degraders |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| ES2779975T3 (es) * | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| WO2015179075A1 (en) * | 2014-05-21 | 2015-11-26 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| BR112017000672A2 (pt) * | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
| EA201890161A1 (ru) * | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| CN109663130B (zh) * | 2017-10-13 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
-
2021
- 2021-07-13 KR KR1020237004543A patent/KR20230039684A/ko active Pending
- 2021-07-13 BR BR112023000675A patent/BR112023000675A2/pt unknown
- 2021-07-13 IL IL299789A patent/IL299789A/en unknown
- 2021-07-13 MX MX2023000589A patent/MX2023000589A/es unknown
- 2021-07-13 AU AU2021307410A patent/AU2021307410A1/en active Pending
- 2021-07-13 WO PCT/US2021/041439 patent/WO2022015736A1/en not_active Ceased
- 2021-07-13 US US18/005,012 patent/US20230330088A1/en active Pending
- 2021-07-13 JP JP2023501802A patent/JP2023534009A/ja active Pending
- 2021-07-13 EP EP21841921.6A patent/EP4178573A4/en active Pending
- 2021-07-13 CA CA3189383A patent/CA3189383A1/en active Pending
- 2021-07-13 CN CN202180049487.0A patent/CN116056699A/zh active Pending
-
2026
- 2026-03-10 US US19/561,954 patent/US20260199339A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513015A5 (enExample) | ||
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| Ducreux et al. | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2024526145A5 (enExample) | ||
| JP2024528039A5 (enExample) | ||
| Kelly et al. | Chemotherapy and targeted therapies for unresectable malignant mesothelioma | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| US20210015787A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| TW201839399A (zh) | 癌症治療 | |
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| CN103533941A (zh) | 治疗恶性实体瘤(包括晚期或转移性恶性实体瘤)的方法 | |
| JP2023527794A5 (enExample) | ||
| CN101969961B (zh) | 胆甾烷醇衍生物的合用用途 | |
| Camera et al. | MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Kim et al. | Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD. | |
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| JP2022522328A5 (enExample) | ||
| CN115487188A (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| EP1427420A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| AU2002342678A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |